Phase II Sunitinib Prog Met AIPC

Inclusion Criteria: * A patient will be eligible for inclusion in this study if he meets all of the following criteria: * Histologically confirmed, adenocarcinoma of the prostate * Stage IV(metastatic) disease, documented on CT, MRI, or X-ray * Progressive disease (PSA or clinical): PSA progression defined as baseline increase followed by any serial increase after 2 weeks; clinical progression by symptomatic or radiologic criteria. * An elevated PSA level of for patients progressing by PSA criteria is required * Currently on androgen ablation hormone therapy (an LHRH agonist or orchiectomy) with testosterone level \<50ng/dL) * Has received 1 or 2 prior chemotherapy regimens (no more than 2). One prior regimen must be docetaxel. * Has an ECOG Performance Status (PS) 0-2 * Is greater than 18 years of age * Meets protocol defined laboratory values * Has adequate cardiac function in the opinion of the Investigator * Has no uncontrolled arrhythmia or hypertension * Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE Version 3.0 Grade less than 1, in the opinion of the Treating Physician * If fertile, patient has agreed to use an acceptable method of birth control to prevent pregnancy for the duration of the study and for a period of 2 months thereafter * Has signed a Patient Informed Consent Form * Has signed a Patient Authorization Form Exclusion Criteria: * A patient will be excluded from this study if he meets any of the following …